Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal Sciences of Pharmacy
Ali, Samad
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Chemical Engineering, Chemistry & Bioengineering Health Professions Medicine & Pharmacology Public Health

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
CRISPR-Integrated Nanogenomic Modulation of β-Cell Epigenome: AI-Assisted Multi-Omics Strategies for Precision Reversal of Diabetes Mellitus Ali, Samad
Sciences of Pharmacy Volume 5 Issue 3 (2026)
Publisher : ETFLIN

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.58920/sciphar0503498

Abstract

Diabetes mellitus remains a global health crisis, with pancreatic β-cell dysfunction as a key pathological feature that current therapies address only palliatively. This narrative review examines an emerging paradigm: the convergence of CRISPR-based epigenome editing, nanotechnology, and artificial intelligence for targeted modulation of the β-cell epigenome. We synthesize evidence on epigenetic dysregulation in diabetic β-cells, critically evaluate preclinical developments in CRISPR epigenome editors and smart nanocarriers for pancreatic delivery, and discuss artificial intelligence applications in guide RNA design and multi-omics integration. Although proof-of-concept studies demonstrate promising synergy, clinical translation remains in its earliest stages. Major challenges including delivery specificity, biosafety, immunogenicity, and regulatory hurdles must be overcome before a precision reversal of diabetes can be realistically contemplated. This review provides a balanced assessment of both the transformative potential and the substantial obstacles facing nanogenomic approaches to diabetes therapy.
Co-Authors